ChemicalsMid capRs 10,500 crRs 12.2 cr traded a day
Close on 2026-08-21
2,052.70
+6.70%
52-week range94% of the way up
1,231.602,108.80
Market cap
10,500 cr
P/E (TTM)
46.6×
industry 36×
EPS (TTM)
44.03
Revenue YoY
+30.2%
Q1 FY27
Profit YoY
+91.4%
Net margin
17.9%
+5.7pt vs a year ago
Growth trend
+30.0pt
vs last quarter’s YoY
1 month
+13.3%
Below 52w high
2.7%
RSI (14)
70
overbought
Daily swing
3.7%
average true range
Volume
2.7×
vs 20-day average
Traded
Rs 12 cr
median day
Close200-day averageMaterial filing
260 sessions · hover for the filing behind a move
1 week
+7.08%
1 month
+13.27%
3 months
+18.62%
6 months
+37.64%
1 year
−0.44%
The read
written from the numbers on this page
The evidence leans constructive7 supporting, 3 against, 0 worth knowing
Supporting
trading 26% above its 200-day average
sitting at 94% of its 52-week range, with little overhead supply from trapped buyers
matches closing in on a 52-week high, which has beaten the market by +0.51 points over 20 sessions across 27,282 past signals
3 of the scans it matches have a positive measured record
5 independent kinds of evidence agree today, which is uncommon
revenue grew 30% year on year in the quarter ending 2026-06-30
net margin has widened from 11.0% to 17.9% across four quarters
Against
down 0% over twelve months
1 of the scans it matches has historically underperformed the market
priced at 47× earnings against an industry median of 36× — 29% above its peers
Worth knowing
nothing the data supports either way
What would change this read: a close below 1,632, its 200-day average; a failure to hold the top of its 52-week range.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
What is working, what is not
read from the filings, with the figure behind every line
Working3
Net profit +91.4% year on year, Rs 49 cr to Rs 95 cr.
+91.4%Rs 49 crRs 95 cr
Profit grew faster than revenue, +91.4% against +30.2%.
+91.4%+30.2%
Net margin moved from 12.2% to 17.9%.
12.2%17.9%
Needs watching
Nothing in the filings stands out either way.
Every figure here is computed from the company’s own filings. The wording is generated directly from the figures.
How it has performed
price return over each window, measured against zero
What the scans say today
14 of 47 matched on 2026-08-21
ALKYLAMINE matches 14 of the 47 scans today, across 5 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.
ALKYLAMINE trades at 47× trailing earnings, below its median of 51× over this window — 9% less expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
AGM / EGM filings were typically +0.00pt vs the market over the next 5 sessions (n=4,362) · Other filing filings were typically -0.08pt vs the market over the next 5 sessions (n=12,093) · Results filings were typically -0.52pt vs the market over the next 5 sessions (n=7,520)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
revenue grew 30% against the same quarter a year earlier
profit rose 91% year on year
net margin widened from 11.7% to 17.9%
Going against it
nothing clear in the filed numbers
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
2026-06-30 · standalone
528
125
95
18.50
17.9%
Q4 FY26
2026-03-31 · standalone
387
61
45
8.87
11.7%
Q3 FY26
2025-12-31 · standalone
354
57
42
8.26
11.9%
Q2 FY26
2025-09-30 · standalone
389
59
43
8.40
11.0%
Q1 FY26
2025-06-30 · standalone
406
66
49
9.67
12.2%
Q4 FY25
2025-03-31 · standalone
386
59
46
9.00
11.9%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average+10.9%
Versus 200-day average+25.8%
Below 52-week high-2.7%
Above 52-week low+66.7%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)70.3
Higher closes in last 53 of 5
Six-month return+37.64%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)3.70%
Volume versus 20-day2.7x
Median daily turnoverRs 12.2 cr
Peers
Chemicals · 44 classified companies
ALKYLAMINE trades at 46.6× trailing earnings against an industry median of 36.0× across 41 other classified companies in its industry — more expensive than them, by 29%. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.